Confo Therapeutics
Stephanie joined Confo Therapeutics as Project Manager for Early Drug Discovery in July 2020 to coordinate new target identification, assessment and prosecution strategies as well as manage the early drug discovery activities.
Stephanie worked for over 10 years at Ablynx (Sanofi) where she headed the discovery phase of multiple therapeutic projects and amassed key expertise in VHH lead optimization. She also led multiple projects focused on platform improvement and extension. Before joining Confo Therapeutics Stéphanie worked for almost 2 years at Biotalys, where she played a key role in establishment of Biotalys’ VHH-based crop protection platform and led multiple discovery projects.
Stephanie has a PhD in biochemistry from KU Leuven (Belgium).
This person is not in any offices
Confo Therapeutics
1 followers
Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery.